Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. Integrins implicated in cell migration into the intestinal tract included α2β2, α4β1, and α4β7; however, the selective activity of vedolizumab against α4β7 integrin has been thought to contribute to its more favorable safety profile compared...
- Mechanism
- Curator reviewed · 1 reference
Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with MAdCAM-1. Vedolizumab does not bind to or inhibit the function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule-1 (VCAM-1).
- Primary indication
- Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.Curator reviewed · 4 structured indications
- Formula / weight
- C6528H10072N1732O2042S42 · 146837.0 Da
- First approval
- Canada, 2015 · United States, 2014 · European Union, 2016
- Code names
- LDP-02 · MLN-0002 · MLN-02
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Vedolizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account